Document:

Exhibit 10.05

 

ASSIGNMENT AGREEMENT

 

THIS AGREEMENT, effective as
of the 15th day of November, 2010, is hereby entered into by and among the University of New Brunswick ("Assignor"), DarkPulse
Technologies Inc. ("Assignee") and for the purpose of section 14 herein, Fantastic North America Inc. ("FNA")

 

WHEREAS Assignor is willing to
sell, assign, and transfer to Assignee its entire right, title and interest in and to certain technologies more particularly described
below on the following terms and conditions;

 

AND WHEREAS Assignor had previously
licensed certain technologies to FNA and now wishes to assign such technologies to the Assignee, an affiliate of FNA, and FNA by executing
this agreement hereby surrenders any and all right and interest in or under any license agreement granted to FNA by the Assignor over
the technologies as more particularly described below,

 

NOW, THEREFORE, IN CONSIDERATION
of the premises and the mutual covenants and agreements set forth hereafter Assignor and Assignee (collectively, the "Parties")
agree as follows:

 

	1.	Assignor hereby sells, assigns and transfers to Assignee, its successors and assigns its entire right,
title and interest in and to Technologies, together with any Canadian or foreign patents claiming each Technologies, all of which are
described by patent filing and annexed as Schedule "A" to this Agreement, and forms part of this Agreement

 

	2.	In consideration of this Agreement, Assignee shall execute and deliver to the Assignor a Convertible
Debenture evidencing indebtedness of the Assignee to the Assignor in an amount of one million and five hundred thousand dollars Canadian
($1,500,000.00 (CDN)), The conversion of such debt into common shares in the Assignee shall occur pursuant to the terms of the aforesaid
Convertible Debenture.

 

	3.	Assignor
                               makes no representations, conditions, or warranties, either express or implied, with respect to the Technologies.
                               Without limiting the generality of the foregoing, the Assignor specifically disclaims any implied warranty,
                               condition, or representation that the Technologies shall correspond with a particular description, is
                               of merchantable quality, is fit for a particular purpose or is durable for a reasonable period of time
                               Assignor shall not be liable for any loss, whether direct, consequential, incidental, or special which
                               Assignee suffers arising from any defect, error, fault, or failure to perform with respect to the Technologies.
                               Nothing in this Agreement shall be construed as a warranty or representation by Assignor as to title to
                               the Technologies or that anything made, used, sold or otherwise disposed of under the Agreement is or
                               will be free from infringement of patents, copyrights, trade-marks, industrial design or other intellectual
                               property rights

 

	4.	Assignee hereby indemnifies, holds harmless and defends the Assignor and, if relevant, its Board of Govemors, officers, employees, faculty,
students, invitees, and agents against any and all claims (including all legal fees and disbursements incurred in association therewith)
arising out of the exercise of any rights under this Agreement including, without limiting the generality of the foregoing, against any
damages or losses, consequential or otherwise, arising from or out of the use of the Technologies or products arising from the Technologies.,

 

	5.	Assignee shall undertake all reasonable registrations and filings required to preserve, protect and
perfect the security interests in the Technologies in favour of the Assignor, including without limitation all reasonable registrations
and filings under provincial or state personal property security legislation and with any applicable intellectual property offices or
registries, and shall provide evidence of same in a written opinion of the Assignee's legal counsel addressed to the Assignor confirming
that the Assignor has a perfected security interest in the Technologies in accordance with the intent of this Article, all in a form and
having content acceptable to the Assignor's legal counsel, and that same shall be provided to Assignor's legal counsel upon request, and
be made available to the Assignor at the Assignee's offices or at any other location as determined by the Assignee from time to time in
the Province of New Brunswick, Canada. This clause shall only remain in force for the duration of the Convertible Debenture Agreement
between the Assignor (University of New Brunswick) and the Assignee (DarkPulse Technologies Inc.) Once the said Convertible Debenture
has been converted to either equity and/or cash by the Assignor in the Assignee this clause will be null and void and of no further force
and effect..

 

 

 

    	 	1	 

     

    

 

	6.	Notwithstanding anything to the contrary herein contained, Assignor hereby warrants and represents to Assignee that Assignor has to the
best of its knowledge, belief and ability made full, complete and timely disclosure of any and all information, research, and other material
documentation with respect to the Technologies, after having made all reasonable searches and inquiries to inform itself with respect
to the contents of this warranty and representation..

 

	7.	Assignor represents and warrants to Assignee, that to the best of its knowledge belief and ability, and after having reviewed the attached
Schedule "A" to this Assignment Agreement, being the Technologies, that the Assignor has received all necessary consents, to
give full and legal effect to this Assignment Agreement, and that the Assignor, upon the request of the Assignee, shall use its reasonable
efforts to obtain and deliver to the Assignee, any and all other documentation, assurances and consents as may be reasonably required
by the Assignee from time to time and at any time in the future, to confirm this warranty and representation.

 

		8	Assignee acknowledges that Assignor has the right to use the Technologies for research and educational
purposes, and to further develop and improve the Technologies and publish its research results pursuant to the Technologies.

 

	9.	Assignor and Assignee agree that, with respect to derivative work and/or intellectual property developed
during a term of two years from the date of execution of this Agreement and which is directly related to the Technologies, that where
such derivative work and/or intellectual property has been developed solely by the Assignor's Drs. Colpitts and Brown, or jointly between
the Assignor's Drs. Colpitts and Brown and the Assignee prior to the signing of this agreement, or where the Assignor has agreed to support
such derivative work be it embodied under a current Canadian Federal funding proposal entitled "Commercialization of Networked Emergency
Management Tools (CONNECT)" or any other Program funded by the Canadian Federal Government that the Assignor and Assignee shall negotiate
reasonably and in good faith and in advance both the method, timing and scope of any publication of said derivative work and/or intellectual
property by or through the Assignor, and the acquisition of said derivative work and/or intellectual property for patenting purposes by
the Assignee more particularly described below, provided however that
the Assignor and Dr. Colpitts shall be free to publish said derivative work and/or intellectual property thirty (30) days after notification
to the Assignee. Dr Brown shall be free to publish any work past, present and/or future as long as it does not contravene any of his duties
of loyalty to the Assignee and/or disclose any confidential information that Dr Brown obtains during the course of his duties as an employee
of the Assignee and/or his role as advisor to the Board of Directors of the Assignee and/or due to his privileged position as significant
shareholder of the Assignee.. Dr Brown warrants and represents that he will be held solely responsible for any damage to the Assignee
and its shareholders including but not limited to litigation and/or litigious damages arising from his publication of any derivative work
and/or intellectual property.

 

	10.	Whereas the Federal Government of Canada as a funding agency role expects that new technologies derived
from the project in Article 9 are held by the Assignor in trust to ensure a later return, and whereas the Assignee agrees to work with
the Assignor to advance the development of the Technologies to the extent the Assignor is able and willing, and given the fact that such
efforts can be supported through funding offsets that reduce the Assignee's investment, the Assignee shall have the right of first refusal
to procure any new technologies derived from a co-sponsored project undertaken by the Assignor (University of New Brunswick) and the Assignee.
Should the option not be exercised by the Assignee within six (6) months of written notice, and having not received in writing a confirming
interest in said option during that period, the Assignor may proceed to seek third party commercialization. In the event the new technologies
are sold to a third party or third parties, the Assignee and Assignor will agree that the Assignor will refund from revenues received
from said new technologies, the difference to the Assignee of the cash investment made in the development of the technology less any funds
received by the Assignee from the Canadian Government, be it from a Provincial or Federal agency, with respect to the cost of the Assignee's
development investment.

 

	11	For clarification, the Assignor and Dr. Colpitts confirm that any work executed under contract, by commission
or at the sole cost to the Assignee belongs to the Assignee absolutely and none of the results derived from such work may be published
or patented by the Assignor at any time unless agreed to by the Assignee in writing.

 

	12	This Agreement shall be governed by and construed in accordance with the laws of the Province of New
Brunswick and any legal proceedings between the Parties with respect to this Agreement shall be submitted to and determined by the Court
of Queen's Bench of New Brunswick.

 

 

 

    	 	2	 

     

    

 

	13.	This Agreement may be modified or amended at any time, upon the mutual agreement in writing of the Parties.

 

	14.	This Agreement shall enure to the benefit of and be binding on the respective successors and assigns of each of the
                                                           Parties, as the case may be

 

	15.	This Agreement constitutes the entire agreement between the Parties and
                                                                                                                           supercedes all previous agreements between the Parties, relating to the subject matter herein.

 

	16.	FNA hereby executes this agreement for purposes of releasing
any and all rights and interest it may have under license agreement granted to it by the assignor in and over the Technologies.

 

IN WITNESS WHEREOF the Parties have executed this
Agreement as of the date first herein set forth

 

 

	 	DARKPULSE TECHNOLOGIES, INC.
	 	 
	 	Per: /s/ Dennis M. O’Leary
	 	Name: Dennis M. O’Leary
	 	Title: President
	 	 
	 	12-7-10
	 	 
	 	FANTASTIC NORTH AMERICA, INC.
	 	 
	 	Per: /s/ Dennis M. O’Leary 
	 	Name: Dennis M. O’Leary
	 	Title: President & CEO
	 	 
	 	12-7-10
	 	 
	 	THE UNIVERSITY OF NEW BRUNSWICK
	 	 
	 	Per: /s/ Gregory Kealey
	 	Name: Gregory Kealey
	 	Title: Provost & Vice President, Research

 

 

I, the undersigned, acknowledge I have read the agreement, agree
with and will adhere to the terms and conditions as well as the applicable policies of the University, and will ensure that all
University personnel working under the agreement will be informed of and will agree to abide by all of the terms and conditions as
well as the applicable policies of the University.

 

 

	/s/ Dr. Bruce Colpitts	Dec 16, 2010
	Name: Dr. Bruce Colpitts	Date

 

 

I, the undersigned, acknowledge I have read the agreement, agree
with and will adhere to the terms and conditions as well as the applicable policies of the University.

 

	/s/ Dr. Anthony Brown	Dec 16, 2010
	Name: Dr. Anthony Brown	Date

 

 

    	 	3Exhibit
10.06

 

CONVERTIBLE DEBENTURE (SECURED)

 

TERM DEBENTURE

 

PRINCIPAL SUM: One Million,
Five Hundred Thousand Canadian Dollars ($1,500,000.00) CDN.

 

INTEREST RATE: Prime (Bank of Canada) overnight rate
plus (1%) per annum

 

ISSUE DATE: April 24th, 2017

 

FOR VALUE
RECEIVED from The University of New Brunswick (the "Payee"), Dark Pulse Technologies Inc. (the "Payor") hereby acknowledges
itself indebted and promises to pay to or to the order of the Payee the sum of One Million, Five Hundred Thousand Canadian Dollars ($1,500,000.00)
CDN (the "Principal Sum") in lawful money of Canada upon presentation and surrender of this debenture at the Payee's offices
at Fredericton, NB (or at such other place as the Payee may designate by notice in writing to the Payor), and shall pay the Payee the
balance from time to time outstanding, in the manner provided in this Debenture, together with interest and all other moneys which may
from time to time be owing under or pursuant to this Debenture upon the earlier of the following (each a "Maturity Date"):

 

		(a)	in the event that the Payor fails to raise $250,000.000 in
capital (the "First Required Capital") or secure contracts valued at $1,000,000.00 from the date that is one (1) year from
the Issue Date or in the event that the Payor fails to raise a further $250,000.00 in Capital (the "Second Required Capital")
or secure contracts valued at $2,000,000.00 from a date that is from the date that is two (2) years from the Issue Date or in the event
that the Payor fails to raise a further $250,000.00 in Capital (the "Third Required Capital") or secure contracts valued
at $2,000,000.00 from a date that is three (3) years from the Issue Date (the First Required Capital, Second Required Capital and Third
Required Capital shall be collectively the "Required Capital"); or

 

		(b)	three (3) years following the Payor achieving a positive earnings before interest,
taxes, depreciation and amortization for two (2) consecutive quarters; or

 

		(c)	the date that is six (6) years from the Issue Date; or

 

		(d)	the Principal Sum and all other payments have been paid in full by the Payor to
the Payee; or

 

		(e)	the date following an event of default; and

 

		(f)	The Payor and the Payee agree that any of clauses (a) through (e), above, may be
amended with the consent of the Payor, upon the request of the Payee, however, the Payor reserves the right to refuse to consent, which
consent can be unreasonably withheld.

 

	1.	INITIAL PAYMENT

 

	1.1	The Payor shall be required to pay the Payee on the date that is one (1) year
from the Issue Date, any and all remaining amounts owed to the Payee regarding the Technology (as defined below), including amounts owed
for Research and Development and all costs associated with protecting and
registering the Technology with the patent office, in the aggregate amount of $42,000 (the "R&D Costs").

 

 

    	 	1	 

     

    

 

	2.	MAINTENANCE PAYMENT

 

	2.1	The Payor shall be required to pay the Payee annually, commencing one (1) year
from the date that is one year from the Issue Date, (i) interest thereon, calculated monthly, at an effective rate of the prime (Bank
of Canada) overnight rate plus 1% calculated monthly, and (ii) all costs
associated with protecting the Technology.

 

	2.2	The installments shall be payable starting on the 24th day of April, 2018 being
the commencement of the second year in this debenture, and continuing until either:

 

		(a)	the Principal Sum and all other payments have been paid in full by the Payor to the
Payee; or

 

		(b)	the commencement of the Payback Period (as defined below).

 

	3.	PAYBACK PERIOD

 

	3.1	Payback on the Principle Sum will commence over a six (6) year period upon the
earlier of the following (each a "Payback Period"):

 

		(a)	three (3) years following the Payor achieving a positive earnings before interest,
taxes, depreciation and amortization for two (2) consecutive quarters; or

 

		(b)	the date that is six (6) years from the Issue Date

 

	3.2	The Payor shall be required to pay the Payee, in quarterly installments over a
six (6) year period commencing from the start of the Payback Period, the following:

 

		(a)	Sixty Two Thousand Five Hundred Canadian Dollars ($62,500.00 CDN ); and

 

		(b)	interest accrued on the Principal Sum on a declining balance; and

 

		(c)	all costs associated with protecting the Technology.

 

	4.	GRACE PERIOD

 

	4.1	The Payor shall have a grace period of thirty (30) clear days from each due date
to make each payment pursuant to the terms of this Convertible Debenture. The Payer's failure to make any payment under the terms of this
Convertible Debenture shall mean that the Payor will be in default under this or any other clause of this Convertible Debenture.

 

	5.	SECURITY

 

	5.1	As security for the due payment of all moneys payable hereunder, the Payor as
beneficial owner hereby mortgages, pledges, assigns, charges and grants a security interest in, to and in favour of the Payee, its successors
and assigns, all its right, title and interest to the Technology consisting of or created whether solely or partially using the patents
filed and received as listed in Schedule "A" as assigned or sold to the Payor by the Payee. In this debenture, the mortgages and charges
hereby constituted are called the "Security" and the subject matter of the Security is called the "Technology".

 

 

    	 	2	 

     

    

 

	5.2	Payor shall undertake all registrations and filing required to preserve, protect
and perfect the security interests in the Technology in favour of the Payee, as may be reasonably required by the Payee, including without
limitation all registrations and filings under the provincial or state personal property security legislation and with applicable Canadian
and U.S. intellectual property offices or registries, and shall provide evidence of same in a written opinion of the Payer's legal counsel
to be delivered to the Payee at closing.

 

	5.3	Until the Security becomes enforceable, the Payor may deal with the Technology
in the ordinary course of its business and for the purpose of carrying on the same provided that the Payor will not, without the prior
written consent of the Payee, create, assume, or have outstanding, except to the Payee, any assignment, license, mortgage, charge or other
encumbrance on any part of the Technology ranking or purporting to rank or capable of being enforced in priority to or pari passu with
the Security, other than any mortgage, lien or other encumbrance upon property, created or assumed to secure all or any part of the funds
required for the purchase of such property or any extension or renewal or replacement thereof upon the same property if the principal
amount of the indebtedness secured thereby is not increased, or any inchoate liens for taxes or assessments by public authorities.

 

	5.4	The Security shall not extend or apply to the last day of the term of any lease
or agreement therefore but, upon the enforcement of the Security, the Payor shall stand possessed of such last day in trust to assign
the same to any person acquiring such term.

 

	5.5	The Payee is the person entitled to receive the money payable hereunder and to
give a discharge hereof.

 

	5.6	The Payor, in consideration of the terms of this Convertible Debenture, shall
enter into a Patent Security and Assignment Agreement and, an Assignment Agreement to be held in Escrow. The Payee shall grant said collateral
security over the Technology in registrable form and shall do all things and execute and deliver all documents (including all assignments,
affidavits and other instruments, in a form suitable for filing with all patent offices where the Technology is registered and recorded)
, including recording the interest against the Technology with the Canadian Intellectual Property Office (CIPO), as may be requested by
Payee from time to time and at any time in order to give effect to this Assignment or to perfect or record the Payee's interest in the
Technology or to maintain the registration or recording of the Technology for a period up until the Principal Sum has been paid in full
by the Payor to the Payee.

 

	5.7	The Payee hereby covenants and agrees, the Technology will be released from escrow
into the possession of Payor upon payment in full by the Payor to the Payee of the indebtedness referenced in this Convertible Debenture.

 

	6.	ROYALTY PAYMENTS

 

	6.1	The Payor, in consideration of the terms of this Convertible Debenture, shall
pay the Payee a two percent (2%) royalty on sales of any and all products or services which incorporate the Technology for a period
of five (5) years commencing one (1) year from the Issue Date.

 

 

    	 	3	 

     

    

 

	7.	ENFORCEMENT

	 	 
	7.1	In the event that the Payor makes default in any payment of principal or interest
required to be made hereunder, including, but not limited to, Payor failing to pay the R&D Costs to the Payee on the date that is
one (1) year from the Issue Date, all principal, interest and other moneys owing under this debenture shall immediately become due and
payable and the Security shall become enforceable.

 

	7.2	Whenever the Security has become enforceable, the Payee may realize upon the Security
and enforce its rights by the following remedies:

 

		(a)	entry into possession or entry into the premises of the Payor; with power to take
possession of the Technology from the Payor;

 

		(b)	proceedings in any court of competent jurisdiction for the appointment of a receiver
(which term as used in this debenture includes a receiver and manager) of the Technology;

 

		(c)	appointment by instrument in writing of a receiver of the Technology and removal
or replacement from time to time of any such receiver;

 

		(d)	to cause the Technology as referenced in the Convertible Debenture to be released
from Escrow in favour of the Payee so as to allow the Payee to deal with the Technology in accordance with the terms of said Agreement,
in accordance with Article 7.4 hereof;

 

		(e)	sale of all or any portion of the Technology;

 

		(f)	filing of proofs of claim and other documents to establish its claims in any proceeding
relative to the Payor; and/or

 

		(g)	any other remedy or proceeding authorized or permitted hereby, or pursuant to any
other agreement to which the Payor and Payee are parties, or by law or equity.

 

	7.3	Upon any failure of the Payor to pay the Payee upon demand of this Convertible
Debenture and upon the exercise by Payee of its option under the Patent Security and Assignment Agreement to become effective, the Payor
does hereby transfer and assign to the Payee all of its right, title and interest in and to the Technology, together with any reissue
, continuation or other extension of the Technology, the invention claimed therein and all proceeds derived from the Technology, including,
without limitation , royalties, license fees and all rights and claims of action that may exist by reason of the infringement of the Technology,
the same to be held and enjoyed by the Payee to the full end of the term for which the Technology is granted, as fully and entirely as
the same could have been held and enjoyed by the Payee if this Assignment had not been made.

 

	7.4	In the event that the Payor breaches any terms or obligations that arise from this
Agreement, the Payee may rely on the terms found within the Escrow Agreement and the Escrow Agent will, without delay, release the Escrow
deposit to the Payee.

 

 

    	 	4	 

     

    

 

	7.5	Such remedies may be exercised from time to time separately or in combination and
are in addition to and not in substitution for any other rights of the Payee howsoever created.

 

	7.6	Any receiver appointed by instrument in writing shall have power to:

 

		(a)	take possession of the Technology and, for that purpose, to take proceedings in
the name of the Payor or otherwise and to make any arrangement or compromise;

 

		(b)	borrow or raise money on the Technology in priority to this debenture or otherwise
for such purposes as may be approved by the Payee; and

 

		(c)	sell or concur in selling the Technology without notice and in such manner as
may seem advisable to the receiver, and to effect such sale by conveying in the name and on behalf of the Payor or otherwise.

 

	7.7	The receiver shall be vested with such other discretions and powers as are granted
in the instrument of appointment and any supplement thereto. The receiver shall, insofar as responsibility for its acts is concerned,
be deemed to be the agent of the Payor and not of the Payee, and the Payor shall be solely responsible for his acts or defaults and for
his remuneration.

 

	7.8	All moneys from time to time received by the Payee or any receiver may be applied
as follows: first, in discharge of all operating expenses and other outgoings affecting the Technology; second, in keeping in good standing
all charges and liens on the Technology having priority over the Security; third, in payment of the remuneration and disbursements of
any receiver; fourth, in payment to the Payee of the moneys payable hereunder; fifth, to any other person(s) entitled thereto by law;
and sixth, the balance, if any, shall be paid to the Payor.

 

	8.	PREPAYMENT

 

	8.1	The Payor may, at any time, when not in default hereunder, on thirty (30) days' notice
in writing to the Payee, prepay all or any portion of the principal amount outstanding hereunder without penalty. Any portion of the principal
owing hereunder designated by such notice for prepayment shall become due and payable, together with all accrued and unpaid interest on
such portion of principal, on the date specified for prepayment in such notice.

 

	9.	CROSS DEFAULT

 

	9.1	If the Payor defaults under any other security or fails to comply strictly with
the terms and conditions of any other agreement, including failure to execute or perform its duties under the Escrow Agreement, now or
hereafter granted to or entered into with the Payee whether as additional security for the due performance of the Payer's covenants hereunder
or otherwise, the Payee shall be at liberty to exercise its rights under this agreement and under any one or more of the other securities
or agreements, either successively or concurrently, to the same extent as if the time for payment of the principal sum hereby secured
had fully come and expired.

 

 

    	 	5	 

     

    

 

	10.	NON-NEGOTIABILITY

 

	10.1	This debenture is not a negotiable instrument and is not transferable or assignable
without the consent of the Payor.

 

	11.	WAIVER

 

	11.1	No consent or waiver by the Payee shall be effective unless made in writing and
signed by an authorized officer of the Payee.

 

	12.	COUNTERPARTS

 

	12.1	This Convertible Debenture may be executed in any number of counterparts, all
of which shall constitute one and the same instrument, and any party hereto may execute this Convertible Debenture by signing and delivering
one or more counterparts. Delivery of an executed counterpart of a signature page of this Convertible Debenture by telecopier or other
electronic transmission (i.e. a "pdf ' or "tif" document) shall be effective as delivery of a manually executed counterpart
of this Convertible Debenture.

 

	13.	NOTICE

 

	13.1	Any demand, notice or other communication in connection with this Debenture shall
be in writing and shall be personally delivered to an officer or other responsible employee of the addressee, mailed by registered mail
or sent by telefacsimile or via electronic mail, charges prepaid, at or to the address or telefacsimile number of the addressee set out
opposite its name below or to such other address or addresses, telex or telefacsimile number or numbers, or via electronic mail, as either
the Payor or the Payee may from time to time designate to the other party in such manner.

 

In the case of the Payor: Dark Pulse Technologies Inc.

 

DarkPulse Technologies Inc.

4400 N Scottsdale Road, Suite 9-720

Scottsdale, Arizona 85251

Tel: (212) 256-1086

Fax: (516) 977-1209

Attn: D. Michael O'Leary

 

Email:

Dennis
O'Leary at : doleary@ darkpulse.com

Anthony
Brown at: abrown@darkpulse.com

  

In the case of the Payee: University of New Brunswick

 

Office of Research Services

3 Bailey
Drive

Sir Howard Douglas Hall, Room
215

Fredericton, N.B. E3B 5A3

Tel: (506) 453-4674

Fax: (506) 458-7600

Attn: David Burns, Vice President Research

 

 

    	 	6	 

     

    

 

	13.2	Any communication which is personally delivered as aforesaid shall be deemed to
have been validly and effectively given on the date of such delivery if such date is a business day and such delivery was made during
normal business hours of the recipient; otherwise, it shall be deemed to have been validly and effectively given on the business day next
following such date of delivery. Any communication mailed as aforesaid shall be deemed to have been validly and effectively given on the
fifth business day following the date of mailing provided that, in the event of an interruption in postal services before such fifth business
day, such communication shall be given by one of the other means.

 

	13.3	Any communication which is transmitted by telefacsimile or other direct written
electronic means as aforesaid shall be deemed to have been validly and effectively given on the date of transmission if such date is a
business day and such transmission was made during normal business hours of the recipient; otherwise, it shall be deemed to have been
validly and effectively given on the business day next following such date of transmission.

 

	14.	All Schedules attached hereto shall be incorporated herein as part of this Convertible
Debenture. In the case of any conflict between this Convertible Debenture and the Schedules, the terms of this Convertible Debenture shall
prevail.

 

	15.	GOVERNING LAW

 

	15.1	This Convertible Debenture shall be interpreted in accordance with the laws of
the Province of New Brunswick, Canada.

 

 

IN WITNESS WHEREOF the Payor has
duly executed this debenture this 24th day of April, 2017

 

 

	UNIVERSITY OF NEW BRUNSWICK	 	DARK PULSE TECHNOLOGIES INC.
	 	 	 	 	 
	 	 	 	 	 
	Name:	/s/ David Burns	 	Name:	/s/ Dennis O’Leary
	Title:	Vice President Research	 	Title:	CFO
	Date:	24 April, 2017	 	Date:	1 May 2017

 

 

 

    	 	7	 

     

    

  

SCHEDULE
"A"

 

The following Schedule is incorporated
by reference

 

The Technology

 

	
     

    lnventor(s)
	
     

    Description
	
     

    Patent or Application #

	
     

    Anthony Brown
	
     

    System and Method for Brillouin
    Analysis (FROBS)
	
     

    US8,643,829

	
     

    

    Bruce Colpitts, Anthony Brown, Kellie A.S. Brown
	
     

    

    System and Method for Resolution
    Enhancement of a Distributed Sensor (Dark Pulse)
	
    US7,245,790

     

    CA2,502,275 (pending)

	
     

    

    Bruce Colpitts, Anthony Brown
	
     

    

    Flexible Fiber Optic Deformation System Sensor and
    Method (ShapeSnake)
	
     

    

    US9,534,965

 

 

	
     

    lnventor(s)
	
     

    Description
	
     

    Patent or Application #

	
     

    Bruce Colpitts, Anthony Brown
	
     

    Dynamic Strain Distributed Fiber
    Optic Sensor
	
     

    As described in Patent
    #

    US7,480,460 abandoned

    January 19, 2017

	
     

    Anthony Brown
	
     

    Phase Locked Loop (DOPLL)
	
     

    As described in Patent
    Application # US12/602,141 abandoned
    June 10, 2015

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]